The viral and non-viral vector manufacturing market is projected to grow at an annualized rate of over 15%, claims Roots Analysis

Published: May 2021

The rapidly growing pipeline of genetically modified therapies reflects the surge in demand for high quality vectors, presenting lucrative opportunities for companies with the capabilities to manufacture viral and non-viral gene delivery solutions

Roots Analysis has announced the addition of Viral Vector Manufacturing Market report to its list of offerings.

Over time, ~15 cell and gene therapies have been approved across the world. Since transgene delivery into biological producing cell lines, gene modified cell-based therapies and the body, is an indispensable aspect of modern drug / therapy development efforts, high quality vectors are required by both medical researchers, drug developers and manufact7uring service providers, alike. In order to save time and costs, many stakeholders in the cell and gene therapy market have opted to outsource their vector manufacturing needs.

To order this 685+ page report, which features 170+ figures and 290+ tables, please visit

Key Market Insights

The market features the presence of over 225 industry players and non-industry players

It is currently dominated by the presence of mid-sized players (51-500 employees), which represent more than 55% of industry stakeholders, worldwide. Of these, ~80% are capable of synthesizing different types of viral vectors, and round 10% of the companies mentioned in the report claim to have expertise in manufacturing plasmid DNA.

Over the time, several new technology platforms have been developed to deal with existing production-related challenges

Majority (85%) of the available technologies are currently focused on viral vectors. The technology  landscape analysis featured in the report, highlights the fact that 55% of the contemporary platforms are meant for the development and production of gene therapies.

Close to 210 partnerships were inked in this market, over the last five years

More than 55% of partnerships were inked post 2017, with the maximum activity being reported in 2020 (till September). Most of the deals (~27%) were manufacturing agreements, followed by product / technology licensing (24%), product development (17%) and R&D (9%) agreements.

Expansion activity in this domain has grown at a CAGR of 97%, between 2015 and 2020

Most of the reported expansions were related to the establishment of new facilities / plants (52%), followed by facility expansions (22%), indicative of the initiatives undertaken by service providers to cope with the rapidly increasing demand for good quality vectors.

The installed vector manufacturing capacity is estimated to be 63,000+ L

The majority share of the available vector manufacturing capacity belongs to companies with both clinical and commercial scale facilities (~70%). In fact, 65% of the estimated global vector producing capacity belongs to the larger and more established stakeholders in the market.

Till 2030, the annual demand for vectors is expected grow at an annualized rate of 21%

Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2030, the demand, in terms of number of patients in need to interventions requiring some form of vector, is projected to be over 220,000.

The developed markets are likely to remain the major contributors, in terms of service revenues, to the market

The majority share of service revenues is anticipated to come from vector manufacturing project for oncological disorders (~55%). By 2030, the need for gene delivery solutions for commercialized therapies, is expected to be responsible for 60% of the annual service revenues, representing a CAGR of 39%.

You Can Download Free Sample PDF Copy of This Report At:

Key Questions Answered

  • Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies?
  • Which global regions are the considered as (contract) manufacturing hubs for vectors and gene therapies?
  • What kind of technologies are used / being developed by stakeholders engaged in this domain?
  • What kind of companies are likely to partner with vector manufacturing service providers?
  • Which types of partnership models are commonly adopted by stakeholders in this industry?
  • What are the different types of expansions that have been undertaken by vector manufacturers?
  • What are the emerging types of viral and non-viral vectors used in the manufacturing of genetically modified therapies?
  • How has the COVID-19 pandemic impacted the viral and non-viral vector, and gene therapy manufacturing market?
  • What is the current, global demand for viral and non-viral vectors, and gene therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The USD 2.5+ billion (by 2030) financial opportunity associated with viral vector, non-viral vector and gene therapy manufacturing market has been analyzed across the following segments:

Scale of operation

  • Lab
  • Clinical
  • Commercial

Type of Vector

  • AAV
  • Adenoviral
  • Lentiviral
  • Retroviral
  • Plasmid DNA
  • Others

Application Area

  • Gene Therapy
  • Cell Therapy
  • Vaccine

Therapeutic Area

  • Oncological Disorders
  • Inflammation & Immunological Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Muscle Disorders
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Others

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America and Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, the anticipated increase in demand for cell and gene therapies, is the most prominent driver of the growth of the vector supply market. The report includes detailed transcripts of discussions held with the following experts:

  • Chief Operating Officer, mid-sized company, UK
  • Business Developer, mid-sized company, Netherlands
  • Chief Executive Officer and President, mid-sized company, Netherlands
  • Chief Executive Officer and Chief Scientific Officer, small company, Germany
  • Former Executive and Scientific Director, small company, Belgium
  • Co-Founder and President, mid-sized company, France
  • Former Director, Netherlands-based company
  • Director, Massachusetts-based organization
  • Scientific Director, France-based organization
  • Managing Director, small company, Japan
  • Scientific Director, small company, US
  • Senior Manager Business Development, mid-sized company, Germany
  • Project Manager, small company, Germany
  • Business Development Manager, small company, US
  • ATMP Key Account Manager, France-based organization
  • R&D Leader, small company, France
  • Director of Marketing and Technical Support, mid-sized company, France
  • Head of Marketing and Technology Development, mid-sized company, Spain
  • Independent Consultant

The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), information related to its manufacturing facilities, proprietary vector manufacturing technology and an informed future outlook.

  • Advanced BioScience Laboratories
  • Aldevron
  • Audentes Therapeutics
  • BioReliance
  • Brammer Bio
  • bluebird bio
  • Emergent BioSolutions
  • FUJIFILM Diosynth Biotechnologies
  • MeiraGTx
  • MassBiologics
  • Spark Therapeutics
  • Vigene Biosciences
  • Biovian
  • Cobra Biologics
  • Centre for Process Innovation
  • FinVector
  • Kaneka Eurogentec
  • Lonza
  • MolMed
  • Novasep
  • Orchard Therapeutics
  • Oxford BioMedica
  • Richter-Helm
  • Sanofi
  • uniQure
  • Vibalogics
  • VIVEbiotech
  • Cell and Gene Therapy Catapult
  • Wuxi AppTec

For additional details, please email at

You may also be interested in the following titles:

  1. Gene Therapies Market
  2. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market
  3. Biopharmaceutical Contract Manufacturing Market
  4. Cell and Gene Therapy CROs Market

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry